What is the story about?
What's Happening?
BioSkryb Genomics has announced the launch of its ResolveSEQ LongRead Early Access Program, aimed at providing researchers with advanced single-cell whole-genome long-read sequencing capabilities. This program offers significantly greater genomic coverage and sensitivity, with 75-92% coverage across sample types from a single cell. The ResolveSEQ LongRead solution utilizes BioSkryb's proprietary Primary Template-directed Amplification technology and Eremid's custom PacBio library preparation, achieving over 70% sensitivity in detecting single-nucleotide variants and complex regions within the same cell. This advancement addresses challenges faced by existing single-cell long-read sequencing technologies, which often suffer from loss of genome coverage due to current amplification methods.
Why It's Important?
The introduction of the ResolveSEQ LongRead solution represents a major advancement in single-cell genomics, offering unprecedented accuracy and uniformity. This technology is particularly beneficial for researchers in fields such as oncology, neurology, and cell and gene therapy, as it allows for the assessment of complex structural rearrangements, gene expansions, and phased SNVs within individual cells. By providing more comprehensive genomic data, this program could lead to significant discoveries in human health and precision medicine, potentially improving diagnostic and therapeutic strategies across various medical disciplines.
What's Next?
Researchers participating in the Early Access Program will be able to leverage the benefits of long-read sequencing to explore complex genomic regions and structural variations. This could lead to new insights into disease mechanisms and the development of targeted therapies. As the program progresses, BioSkryb Genomics and Eremid Genomic Services may expand their offerings and collaborations, further enhancing the capabilities of single-cell sequencing technologies.
AI Generated Content
Do you find this article useful?
